Strs Ohio Has $9.05 Million Stake in Insmed, Inc. $INSM

Key Points

• Strs Ohio increased its stake in Insmed by 76.6% in Q4, owning 52,016 shares valued at approximately $9.05 million after adding 22,562 shares.
• Significant insider selling has occurred recently: COO Roger Adsett sold 88,060 shares for about $14.5 million, and insiders have sold 174,589 shares (≈$27.44 million) in the past 90 days, leaving insiders with 2.10% ownership.
• Analysts remain largely bullish with a consensus “Buy” rating and an average price target of $213.23 (several firms have raised targets, e.g., Barclays to $237), while the stock trades near $140, implying notable analyst-implied upside.

Strs Ohio raised its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 76.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 52,016 shares of the biopharmaceutical company's stock after buying an additional 22,562 shares during the period. Strs Ohio's holdings in Insmed were worth $9,053,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in INSM. EULAV Asset Management acquired a new position in shares of Insmed in the 3rd quarter valued at $12,961,000. Artisan Partners Limited Partnership increased its position in shares of Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company's stock valued at $711,076,000 after acquiring an additional 1,623,342 shares during the period. Atika Capital Management LLC acquired a new position in shares of Insmed in the 3rd quarter valued at $13,681,000. Nisa Investment Advisors LLC increased its position in shares of Insmed by 374.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 10,466 shares of the biopharmaceutical company's stock valued at $1,507,000 after acquiring an additional 8,261 shares during the period. Finally, Nordea Investment Management AB acquired a new position in shares of Insmed in the 4th quarter valued at $3,492,000.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Barclays upped their target price on Insmed from $231.00 to $237.00 and gave the company an "overweight" rating in a research report on Wednesday, April 1st. Truist Financial set a $205.00 price target on shares of Insmed in a report on Monday, January 12th. Bank of America upped their price target on shares of Insmed from $211.00 to $213.00 and gave the company a "buy" rating in a report on Tuesday, March 24th. Roth Mkm reaffirmed a "buy" rating and issued a $212.00 price target on shares of Insmed in a report on Friday, April 17th. Finally, Jefferies Financial Group assumed coverage on shares of Insmed in a report on Monday, March 16th. They issued a "buy" rating and a $228.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $213.23.

Insider Transactions at Insmed

In other news, COO Roger Adsett sold 88,060 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the sale, the chief operating officer directly owned 106,810 shares of the company's stock, valued at $17,584,130.30. This represents a 45.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Alexander Smith sold 19,638 shares of the firm's stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the transaction, the insider directly owned 51,871 shares in the company, valued at $7,831,483.58. This represents a 27.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 174,589 shares of company stock valued at $27,441,807 in the last ninety days. 2.10% of the stock is currently owned by corporate insiders.

Insmed Price Performance

NASDAQ:INSM opened at $140.01 on Tuesday. Insmed, Inc. has a one year low of $63.81 and a one year high of $212.75. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The firm has a market cap of $30.22 billion, a price-to-earnings ratio of -21.84 and a beta of 0.89. The firm's fifty day moving average is $147.89 and its two-hundred day moving average is $166.24.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm had revenue of $263.84 million for the quarter, compared to analysts' expectations of $263.97 million. During the same period in the previous year, the company earned ($1.32) earnings per share. The company's revenue was up 152.6% compared to the same quarter last year. Research analysts expect that Insmed, Inc. will post -2.51 EPS for the current year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.